Days
Hours
Minutes
Seconds
-40%
on all our subscriptions*
Spring Sale
Enjoy this offer
* See conditions under "Our services"

Valuation: Charles River Laboratories International, Inc.

Capitalization 8.71B 7.52B 6.79B 6.5B 11.82B 803B 12.36B 80.13B 32.13B 384B 32.71B 32B 1,378B P/E ratio 2026 *
22.7x
P/E ratio 2027 * 18.7x
Enterprise value 8.71B 7.52B 6.79B 6.5B 11.82B 803B 12.36B 80.13B 32.13B 384B 32.71B 32B 1,378B EV / Sales 2026 *
2.26x
EV / Sales 2027 * 2.24x
Free-Float
97.96%
Yield 2026 *
-
Yield 2027 * -
03-09 Baird Adjusts Price Target on Charles River Laboratories International to $197 From $193 MT
03-05 Therna Biosciences, Inc. Announces Collaboration with Charles River to Advance Single-Patient Personalized RNA Therapeutics CI
03-03 Charles River Laboratories International, Inc. Presents at TD Cowen 46th Annual Health Care Conference, Mar-03-2026 09:50 AM
02-25 IQVIA Holdings Inc. (NYSE : IQV) entered into a definitive agreement to acquire European Discovery Services Assets from Charles River Laboratories International, Inc. (NYSE : CRL) for $155 million. CI
02-25 GI Manager L.P. signed a definitive agreement to acquire Contract Development and Manufacturing Products and Services and Cell Solutions Businesses from Charles River Laboratories International, Inc.. CI
02-25 UBS Adjusts Price Target on Charles River Laboratories International to $175 From $170, Maintains Neutral Rating MT
02-25 Sector Update: Health Care MT
02-25 Charles River Laboratories to Sell Certain European Assets, Businesses; Full-Year 2026 Guidance Updated MT
02-25 Charles River raises annual profit view as it sells underperforming assets RE
02-25 Charles River Laboratories International, Inc. Revises Earnings Guidance for 2026 CI
02-25 (CRL) Charles River Laboratories Expects 2026 Adjusted EPS Including Impact of Planned Divestitures Range $10.80 - $11.30 MT
02-20 Rothschild & Co Redburn Adjusts Charles River Laboratories PT to $200 From $211, Maintains Buy Rating MT
02-20 Mizuho Securities Adjusts Charles River Laboratories Price Target to $175 From $215, Maintains Neutral Rating MT
1 day-2.78%
1 week-2.09%
Current month-3.62%
1 month-5.08%
3 months-11.71%
6 months+12.24%
Current year-13.76%
1 week 166.82
Extreme 166.82
182.65
1 month 146.33
Extreme 146.33
183.11
Current year 146.33
Extreme 146.33
228.88
1 year 91.86
Extreme 91.8609
228.88
3 years 91.86
Extreme 91.8609
275
5 years 91.86
Extreme 91.8609
460.21
10 years 67.2
Extreme 67.2
460.21
Manager TitleAgeSince
Chief Executive Officer 75 31/12/1991
Director of Finance/CFO 49 28/09/2025
Chief Tech/Sci/R&D Officer 45 11/01/2026
Director TitleAgeSince
Chairman 75 31/12/1999
Director/Board Member 69 04/07/2017
Director/Board Member 70 30/09/2019
Change 5d. change 1-year change 3-years change Capi.($)
-2.85%-2.09%-1.77%-15.07% 8.71B
+0.60%-3.36%-7.98%-6.22% 44.96B
+1.93%+3.54%+26.75%+42.24% 33.54B
+0.98%-13.63%+16.43%+43.10% 30.24B
-2.71%-0.08%-7.92%-11.88% 29.97B
+0.47%-0.55%+171.43%+381.41% 19.78B
+0.84%+0.54%+74.05%+126.44% 14.73B
-1.49%+1.76%+40.36%+169.95% 13.58B
+0.85%-3.12%+22.63%+1.01% 12.97B
+1.53%-3.38%+135.88%+123.79% 12.45B
Average +0.08%-1.65%+46.99%+85.48% 22.09B
Weighted average by Cap. +0.25%-1.67%+35.29%+68.89%

Financials

2026 *2027 *
Net sales 3.86B 3.33B 3.01B 2.88B 5.24B 356B 5.48B 35.5B 14.24B 170B 14.49B 14.18B 610B 3.9B 3.36B 3.04B 2.91B 5.29B 359B 5.53B 35.84B 14.37B 172B 14.63B 14.31B 616B
Net income - -
Net Debt - -
Logo Charles River Laboratories International, Inc.
Charles River Laboratories International, Inc. specializes in the development of products and services in the field of research and non-clinical drug development for pharmaceutical companies, government agencies and academic institutions. Net sales break down by activity as follows: - discovery and safety assessment services (59.8%): discovery services for the identification, screening and selection of main compounds for the development of new drug candidates, and in vivo and in vitro testing, including pharmacokinetic, bioanalytical, metabolic, toxicological and pathological studies, for the safety assessment of pharmaceutical products, medical devices, animal health products, chemical and agrochemical products and biocides; - development and sale of research models and related services (21.1%): mice, rats, immunodeficient models, rabbits, guinea pigs, hamsters, etc. The group also offers primary cells and specialized products (bioconservation products, freezing media for cell cultures, antigens, peptides, humanized mouse models, etc.) for the development and manufacture of new cell therapies ; - development of solutions used in drug manufacturing processes (19.1%): products and services for microbiological testing, in vitro testing, endotoxin testing, microbial identification, development, manufacturing of avian vaccines, etc. The group also offers contract manufacturing services for cell and gene therapies. Net sales break down by source of income between sales of services (80.9%) and sales of products (19.1%). Net sales are distributed geographically as follows: the United States (53.3%), Europe (27.5%), Canada (12.5%), Asia/Pacific (5.1%), and other (1.6%).
Employees
19,000
Date Price Change Volume
10/03/26 172.28 $ -2.66% 217,006
09/03/26 176.99 $ +1.45% 1,029,086
06/03/26 174.46 $ -3.78% 1,078,851
05/03/26 181.32 $ +0.97% 1,145,086
04/03/26 179.58 $ +2.21% 742,853
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
18
Last Close Price
176.99USD
Average target price
197.47USD
Spread / Average Target
+11.57%

Quarterly revenue - Rate of surprise

SPRING SALE -40%: The Best Tools Reserved for Subscribers to Identify Tomorrow's Top Investments!
d
:
:
BENEFIT NOW